{"schema_version":"secwatch.filing_event.v1","accession":"0001171520-21-000516","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.905497+00:00","generated_at":"2026-06-28T10:30:39.504998+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ClearPoint Neuro Q3 revenue $4.6M record, up 30% YoY; reaffirms FY guidance","bullets":["Record revenue $4.6M (+30% YoY); biologics/drug delivery $2.1M (+39%).","Functional neurosurgery revenue $2.2M (+17%); capital equipment $0.4M (+78%).","Gross margin 68% vs 74% due to inventory reserves and overhead.","R&D spend $2.6M (+130%) driven by headcount and platform expansion.","Cash $57.7M; guidance: FY revenue $16-17.5M, case volume 900-1000."],"urls":{"canonical":"https://secwatch.observer/filing/0001171520-21-000516","json":"https://secwatch.observer/filing/0001171520-21-000516.json","markdown":"https://secwatch.observer/filing/0001171520-21-000516.md","text":"https://secwatch.observer/filing/0001171520-21-000516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000117152021000516/0001171520-21-000516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000117152021000516/eps9899.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:30:39.504998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}